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ABSTRACT
Uterine fibroids (UFs) are common benign tumors of the female genital tract, diagnosed in almost one-quarter of women 
of reproductive age. UFs may cause numerous clinical symptoms, including prolonged or heavy menstrual bleeding, pelvic 
pressure symptoms, pain, infertility and others. Submucous fibroids arise from the muscular part of the uterus and pen-
etrate into the uterine cavity. They are mostly managed with the use of hysteroscopic myomectomy (HM), which provides 
direct visualization from the transcervical approach. The sheer number of HM standards and techniques is reason enough 
to review the available literature about HM-related complications. 
HM is a safe and effective treatment in patients with the normal size of the uterus and with no more than a few UFs. The 
procedure should not be initiated without adequate preparation and diagnosis, using the best methods available. 
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INTRODUCTION
Uterine fibroids (UFs) are common benign tumors of 
the female genital tract. They are diagnosed in almost 
one-quarter of women of reproductive age [1]. UFs may 
cause numerous clinical symptoms, including prolonged 
or heavy menstrual bleeding, pelvic pressure symptoms or 
pain, infertility and obstetric complications, but are mostly 
asymptomatic [1]. 
Typically, UFs were divided into three groups (submu-
cous, intramural and subserosal), but nowadays the Inter-
national Federation of Gynecology and Obstetrics (FIGO) 
fibroid classification, where fibroid location is determined 
in relation to the uterine cavity (with submucosal fibroids 
named class 0, 1 or 2) is more commonly used [2]. In 2017, 
Laughlin-Tommaso et al., published a study about clinical 
limitations of the FIGO classification, signaling the need for 
its additional validation [3]. STEPW, which is an acronym of 
size, topography, extension of the base, penetration and 
wall, is a less popular classification for submucous UFs by 
Lasmar et al. [4]. STEPW allows for a greater correlation with 
complete or incomplete removal of the uterine fibroid by 
hysteroscopic myomectomy (HM) [5]. Clinically symptomatic 
intramural and subserosal fibroids are usually treated with 
laparoscopy or open surgery. Attempts to remove intramural 
UFs with the use of HM have been reported but, so far, the 
effects have been questionable [6]. Submucous fibroids arise 
from the muscular part of the uterus and penetrate into the 
uterine cavity, which is why they can be managed with the 
use of hysteroscopy, the current ‘gold standard’. Hysteros-
copy provides direct visualization of the endometrial cav-
ity and submucous fibroids. In general, only symptomatic 
tumors are operated upon but HM has sometimes been 
advised in asymptomatic women, especially if they wish to 
conceive in the future [7]. 
In order to achieve optimal conditions during HM, the 
uterine cavity needs to be distended by a medium. New fiber 
optic technologies and surgical accessories have improved 
visual resolution and hysteroscopy in general [8]. Also, mul-
tiple hysteroscopic techniques to excise UFs are currently 
available [9]. Hysteroscopic resection with a monopolar loop 
electrode is the most prevalent method. Some UFs, espe-
cially those located deeper in the myometrial wall, require 
advanced skills and better instrumentation [9]. Prior to UF 
removal, most patients are diagnosed with the use of an ul-
trasound, and some also undergo a diagnostic office hyster-
oscopy, which can help to determine patient eligibility [10]. 
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Some gynecologists use sonography-guided hysteroscopy 
as a method of choice in more complicated cases [9]. In 
difficult cases, pre-treatment is also advisable [11]. A study 
by Ferrero et al., showed that a ulipristal acetate preopera-
tive treatment increased the complete resection rate and 
decreased the operative time in difficult HMs [12]. However, 
the European Medicines Agency (EMA) has recently issued 
a warning about the risk of liver failure after ulipristal ac-
etate use [13]. 
HM might be very easy or extremely difficult, depend-
ing on various patient- or equipment-related factors. Only 
proper diagnosis and surgeon expertise may produce good 
results and prevent complications.
The availability of a hysteroscopic resectoscope no long-
er presents a problem and the number of centers which treat 
advanced cases of UFs continues to grow. That is why, the 
authors of this manuscript decided to present a review of 
the main complications which can occur during HM. Advice 
on how to prevent complications or tackle them has also 
been included.
MATERIAL AND METHODS
This article presents an up-to-date review of the publica-
tions about HM-related intra- and peri-operative complica-
tions. A literature search for this review was conducted in 
PubMed of the National Library of Medicine from January 
2000 to November 2017 using the following key words: “hys-
teroscopy”, “myomectomy”, “hysteroscopic myomectomy”, 
“morcellation”, “uterine perforation’, “excessive bleeding”, 
“incomplete resection”, “infection”, “intravascular absorption 
syndrome”, “venous intravasation”, and “venous air embo-
lism”. During the search, the key words were combined into 
pairs, which resulted in: “hysteroscopy” and “myomectomy 
— 259; “hysteroscopy” and “surgical complications” — 1207; 
“hysteroscopy ” and “morcellation” — 41; “hysteroscopy” and 
“uterine perforation” — 179; “hysteroscopy” and “excessive 
bleeding” — 37; “hysteroscopy” and “incomplete resection” 
— 38; “hysteroscopy” and “infection” — 140; “hysteroscopy” 
and “intravascular absorption syndrome” — 5; “hysteros-
copy” and “venous intravasation” — 5; and “hysteroscopy 
venous air embolism” — 14 results. The search for “hyst-
eroscopic myomectomy” alone presented 286 results. Ad-
ditional important articles and reviews from other databases 
(e.g. Cochrane, Web of Science and Scopus) were consid-
ered, when relevant. Articles published in languages other 
than English were excluded. The emphasis of the review 
was to critically review data about HMs, the safety of the 
procedure, and possible adverse outcomes.
DISCUSSION
Complications during hysteroscopy are rare and depend 
mostly on the difficulty of the surgery. Uterine perforation, 
infection, excessive bleeding, venous intravasation, and 
long-term complications like intrauterine adhesions account 
for the most common surgery-related problems [14].
Uterine perforation
Uterine perforation is the most common HM-related 
complication [15–17]. However, in a multicenter study by 
Aydeniz et al., in nearly 22,000 patients, it was reported only 
in 0.15% of the cases [16]. The causes of uterine perfora-
tion vary, with the too deep resection of the uterine fibroid 
in unfavorable conditions or a perforation during cervical 
dilatation among the most frequent ones. 
A conservative approach and observation are sufficient 
in most cases of uterine perforation. However, thorough 
diagnosis in the case of hot loop, damage or morbidity 
cannot be omitted [8]. In the middle line perforation, seri-
ous complications are seldom reported but in the case of 
lateral damage or damage to the cervix, hemorrhage or 
retroperitoneal hematoma may occur more often. Laparos-
copy or laparotomy are recommended to fully assess the 
damage to the uterus and the surrounding structures such 
as the bowel or the urinary bladder [18]. Thermal damage to 
these structures can also be postponed and appear 5 days 
to even 2 weeks postoperatively [18]. Still, even if there is 
no typical injury, the patient should always be advised to 
report for emergency control in case of symptoms like fever, 
abdominal pain, nausea or vomiting [18].
 According to Mazzon et al., thin free myometrial margin 
(FMM) is the major risk factor for this kind of complica-
tion  [15]. The value of 10 mm in the myometrial margin 
allows the surgeon to consider hysteroscopy as a safe proce-
dure [15]. According to other sources, it can even be as low 
as 5 mm [8]. Mazzon et al., described the cold loop technique 
which in their opinion is much safer than the electric loop 
due to the lower risk of injury to the adjacent organs [15]. 
These authors also pointed out that the cold loop technique 
(mechanical loops of Mazzon; Karl Storz, Tuttlingen, Ger-
many) using the blunt dissections constitutes a lower risk 
for the subsequent pregnancies in those women [15]. It is 
known that an extremely hot electric loop can damage the 
surrounding structures e.g. blood vessels, bladder or bowel, 
even in indirect contact (without uterine perforation). Dur-
ing difficult HMs, the surgeons do not always remember that 
the loop may cause delayed damage. In cases where FMM is 
very thin, it is important to consider using a cold loop [15], 
intraoperative ultrasound [9], or a two-port operation (with 
a direct laparoscopic supervision), in order to track the ex-
act position of the surgeon. The two-port surgery might 
be more invasive than the ultrasound-guided one, but no 
other technique offers such control in the operative field. It is 
sometimes worth considering if patient outcome will not be 
more favorable after laparoscopic myomectomy, especially 
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in case of larger UFs. The use of cold loops should be con-
sidered due to the exceptionally good results [15], and to 
prevent the abovementioned complications.
Some centers have dramatically reduced their complica-
tion rate by using intraoperative ultrasonography [9], which 
has considerable advantage over the ordinary pre-operative 
ultrasound as FMM is not a stable parameter [19]. Also, tran-
srectal ultrasonography can be an interesting alternative to 
the transabdominal scanning [20]. Apart from the size, the 
precise measurement of the UF volume is of paramount im-
portance [8, 9]. According to Emanuel, 3D ultrasonography 
is a great tool for proper preoperative evaluation, with good 
reproducibility [8]. The complication rate is also decreasing 
due to better operator skills, which is yet another proof that 
it is necessary to constantly train personnel [9, 15, 21].
A thorough gynecological ultrasound scan, with the 
measurement of the fibroid volume and the residual uterine 
wall thickness, is the key point in safe HM. The volume of the 
removed tissue should be assessed during the procedure. 
If the volume is assessed pre-operatively and is assumed to 
be high, the surgeon should proceed with greater caution. It 
should be emphasized that a person undertaking high-risk 
hysteroscopy needs to have good laparoscopic skills (or be 
experienced in open surgery) to repair any possible damage. 
During laparoscopy, if the operator has the skills to suture 
the uterine muscle, the injury can be repaired in a very short 
time. Of course, laparotomy may always be performed, but 
for the patient who has already decided to have a minimally 
invasive hysteroscopy, laparoscopy will be better tolerated, 
due to better cosmetic effect, which in turn will provide 
greater overall satisfaction.
Bleeding
Bleeding can be associated with the perforation but 
can also occur due to other causes (bleeding may occur from 
the endometrium, myometrium, or the surrounding vessels 
[17, 18, 22]. According to Munro and Christianson, anemic 
patients who require HM can be rendered amenorrheic be-
fore the surgery using hormonal treatment (GnRH analogs or 
SPRMs), and then supplied with adequate iron supplementa-
tion to increase their blood morphology and iron stores [18]. 
Preoperative blood transfusion can be considered in cases 
when surgical delay could be dangerous [18].
Bleeding may have different severity — from scant to 
severe hemorrhage. The depth of the resection should be 
limited in the lateral wall and the isthmus area, where the 
risk for injuring the large myometrial branches of the uterine 
artery is elevated [18]. In case of small bleeding, it is some-
times necessary to temporarily increase the fluid pressure to 
gain more visualization and attempt coagulation, e.g. with 
the ball electrode [18], although in case of severe bleeding 
the surgeons should also use some uterotonics. According 
to Emanuel, small bleeding might be arrested by sponta-
neous uterine contraction [8, 23]. Some types of bleeding 
may respond to the administration of vasopressin injection 
(dilute vasopressin solution (0.05 U mL-1) [18, 22], or utero-
tonics, e.g. oxytocin (e.g. 5 to 10 IU intravenously) [22] or 
misoprostol (600–1000 μg). The use of oxytocin was tested 
in hysteroscopic endometrial resection [24], but there is still 
not enough data about its use in HM. In cases where the 
effect of uterotonics is insufficient, an intracavitary balloon 
tamponade might be used, e.g. a Foley catheter filled with 
30–50 mL of fluid, which is consistent with the literature re-
ports [18]. In difficult cases, laparoscopic or open surgery su-
turing or hysterectomy remain the available alternatives. In 
general, adequate preparation is vital, especially before 
the excision of large UFs. It is also advised to remember 
that the risk for bleeding increases with the depth of the 
excision. Type 2 fibroids > 6 cm in diameter constitute the 
limits of this endoscopic technique [9]. Attempts to tackle 
type 3 UFs using HMs have been reported but in such cases 
highly experienced surgeons are necessary due to the risk 
for intrauterine adhesions and other complications.
Incomplete resection
According to the available literature, complete UF re-
moval accounts for almost 90% and 60–80% of surgical 
interventions in G1 UFs and G2 UFs, respectively [25]. In 
a study by Cammani et al., complete resection of large 
(< 5 cm in diameter) fibroids was achieved in 81.8% of the 
patients. Interestingly, in a study by Korkmazer et al., no 
remnants were observed in patients after hysteroscopy 
with the use of perioperative transabdominal ultrasound 
surveillance [9]. 
Some authors treat incomplete removal as a severe 
complication [9]. However, it cannot be strictly treated as 
a complication. Sometimes incomplete removal signifies 
well-understood caution, which aims to reduce the risk for 
complications, e.g. in case of difficult operating conditions, 
suspected operative hysteroscopy intravascular absorption 
(OHIA) syndrome, or technical deficiencies. It should be em-
phasized that a two-step procedure can sometimes reduce 
the overall risk and result in the same outcome [25]. It is 
also possible that in case of the inhibition of the UF-derived 
symptoms (especially when the indication was abnormal 
uterine bleeding), the remaining part of the UF may become 
devascularized and undergo spontaneous resorption [8, 25]. 
However, this procedure does not apply in case of infertil-
ity, where the two-step procedure should be proposed [8].
Morcellation
During HM of the larger UFs, the resected fragments often 
disturb visualization, and these parts have to be removed 
from the uterine cavity. A hysteroscopic morcellator was 
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developed precisely for that task. It allows for a fast and auto-
matic tissue removal and reduces the time of surgery [8, 26]. 
However, morcellation is not free from complications [27].
The fibrotic tissue which has been deformed must be 
removed from the uterine cavity. This is done most often 
by holding the tissue remnant using the hysteroscope loop 
and part by part extraction – this provides the best ac-
curacy [8]. Due to the fact that such a procedure must be 
repeated several times in case of multiple or large UFs, it 
raises the risk for complications, e.g. venous air embolism 
(VAE) [18, 28]. Recently, a hysteroscopic morcellation system, 
somewhat similar to that used in laparoscopy, has been 
invented [8, 23, 27]. In a sample TRUCLEAR® system, the tis-
sue is sucked into a special window, excised and extracted 
without additional coagulation. In those cases, standard 
saline medium is used for distension and irrigation. Studies 
about hysteroscopic morcellation are ongoing, but their 
results have been most encouraging due to low complica-
tion rates. It might even be a breakthrough in the field of 
HM [27]. Good results, e.g. in case of subsequent pregnan-
cies after HM with morcellation using the MyoSure® device, 
were confirmed by Chen et al., as most subjects became 
pregnant after the surgical intervention [29]. 
The limitations to the use of hysteroscopic morcellators 
remain to be fully elucidated. According to Noventa et al., 
the operative time depends on volume, density and type of 
tissue. These authors advise caution in case of large volume 
UFs which present with high density on ultrasound scan [30].
After the alarm raised by the US Food and Drug Adminis-
tration (FDA) in 2014 about power morcellation during lapa-
roscopy and the related consequences, the debate among the 
experts continues. FDA stated that morcellation is a danger-
ous technique, causing abnormal spreading of cells within 
the abdominal cavity [31]. According to the current data, 
the risk for malignancy spread by morcellation is extremely 
low (around 0.06%) [32, 33]. There is also a study about the 
risk of malignant cells intraabdominal spread in women with 
endometrial cancer only during hysteroscopy [34].
Infection
Kerkvoorde et al., reported extremely low risk for infec-
tion during office hysteroscopy [14]. Agostini et al., assessed 
the risk for infection during hysteroscopy to be 1.42% [35], 
while according to other authors the risk was even smaller 
[14, 16, 18]. It should be emphasized that the risk for infec-
tion increases with manipulation of the cervix, such as dilata-
tion for example [14]. The problem of HM-related infection 
is so rare that there is no consensus about the prophylactic 
antibiotics [18]. Nappi et al., found no differences in the risk 
for infection between groups of patients receiving prophy-
laxis and controls [36]. Antibiotic prophylaxis should be 
considered in case of all patients, especially if their medical 
history is unclear or the patient has a history of recurrent 
inflammatory conditions of the reproductive tract.
Venous intravasation/operative hysteroscopy 
intravascular absorption (OHIA) syndrome
OHIA syndrome is such a rare complication that some 
surgeons do not remember it might occur. 
Fluid media are used for operative procedures to al-
low the use of electrosurgery. Also, continuous irrigation 
results in more clear vision. Ringer’s solution or 0.9% saline 
solution are the most common fluids used as distension 
media in modern HM [8]. These media are isotonic and are 
applicable to bipolar methods, and they are also considered 
to be much safer than hypotonic media [8, 18, 22, 28]. Gas 
media (e.g. carbon dioxide) are not applicable in operational 
hysteroscopies. There are various mechanisms by which 
the fluid enters the circulatory system — through the en-
dometrium, fallopian tubes or by vessels opened during 
UF resection. The problem with these media is that large 
volumes can be absorbed into the circulatory system when 
the myometrial vessels are opened, which may cause fluid 
overload, electrolyte imbalance, and serious complications, 
e.g. pulmonary edema or cardiac failure. Patients who de-
velop fluid overload will experience headache or drowsiness, 
convulsions or apnea, or vomiting [8, 18]. The occurrence 
of such symptoms, even without reaching the fluid limits, 
requires additional diagnostic tests and should be treated 
as a complication [37].
In general, the best approach to prevent the OHIA syn-
drome is a scrupulous fluid balance in real life surgery. There 
are different systems which determine the volume of the 
fluid and fluid that has drained, but these are always merely 
the estimated values. It is important to remember about the 
possibility of complications of excessive venous absorption. 
In the long-term, it is important to monitor the amount of 
fluids used in relation to that which has returned (bucket, 
floor, system etc.) [18]. 
The use of isotonic distention media reduces the risk 
for complications as they are safer than hypotonic solutions 
[27]. In a work by Jansen et al., the rate of complications as-
sociated with the medium was assessed as 0.2% [17]. A low 
complication rate was also proven in a study by Aydeniz et al. 
[16]. The risk for fluid absorption is even greater during HMs, 
when large vessels are opened, facilitating the absorption 
of fluid under high pressure [37]. Prolonged HM is another 
high-risk procedure [37]. 
In case of isotonic media, the upper limit of the absorbed 
fluid has been set at 2,500 mL [38]. Minor OHIA, caused by 
isotonic media, can be successfully treated with standard 
diuretics, e.g. furosemide. The limit for hypotonic media is 
lower and has been reported at 1000 mL [26, 37]. This value 
has been based on the fact that when the patient absorbs 
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about 1,000 mL of a 1.5% glycine solution, the sodium con-
centration drops by about 8–10 mmol/L [22, 37].
As mentioned above, large volumes of hypotonic media 
used in monopolar techniques (5% mannitol, 1.5% glycine) 
constitute the problem. The risk for complications is very 
high and might present as water poisoning, lung or brain 
edema, and hyponatremia [8, 18, 38]. In such cases, the 
treatment usually involves co-operation with anesthesiolo-
gists and incorporating high-percentage sodium chloride 
boluses to initially compensate sodium deficiency. Impor-
tantly, clinicians should not quickly compensate for hypona-
tremia due to the threat of additional complications, such 
as pons myelinolysis. Determination of the amount of fluid 
intake presents an additional challenge. Different amounts 
will be acceptable for a young healthy woman than older 
woman with chronic kidney or heart disease [37]. In high-risk 
women, the maximum amounts of the absorbed fluid have 
been estimated at 1500 mL and 750 mL for isotonic and 
hypotonic media, respectively [38]. 
Venous air embolism
A venous air embolism (VAE) is one more type of compli-
cation which might occur during HM. The available literature 
describes the seriousness of the problem, allowing surgeons 
to learn how to deal with such cases [18, 28]. An interesting 
study on VAE was published in Norway on the basis of three 
cases from their center [28]. 
VAE is a rare complication and the gas embolus may 
come from the medium used to expand the uterus during 
electrocoagulation or directly from the air in the operating 
room. The gas entering the cardiovascular system can cause 
arrhythmia, pulmonary hypertension, gas exchange dis-
orders, and, in the worst-case scenario, can lead to death 
[28, 39]. A patient who develops VAE will report chest 
pain, breathing disturbances, shortness of breath, or may 
cough [39]. Some authors may find it unlikely, but asympto-
matic gas in the right heart atrium after hysteroscopy is not 
a rare phenomenon [28, 40]. More commonly used bipolar 
systems, which are less likely to cause OHIA, produce more 
air bubbles and increase the risk for VAE. Echocardiography 
is a good way to monitor a patient for VAE (although it is 
a problematic matter to always have a continuous echocar-
diography during HM). The second most common method is 
the monitoring of carbon dioxide concentration (end-tidal 
CO2 – EtCO2). Even small air bubbles will affect the EtCO2 re-
duction, so the problem will be quickly noticed. According 
to Storm et al., the EtCO2 alarm should be set at about 
4 mm Hg below the patient baseline, with high frequency 
(e.g. every minute), less frequent measurements may cause 
delays in the diagnosis of complications [28]. If an alarm is 
triggered, the procedure is immediately interrupted until 
the EtCO2 level returns to baseline [28].
In case of a suspicion or diagnosis of VAE, HM should 
be immediately terminated. An attempt to locate the gas 
inlay location and the removal of the hysteroscope should 
be performed as well. According to Munro et al., 100% oxy-
gen should be applied, the cervical canal should be closed 
instrumentally, and the patient should be placed in the 
Trendelenburg position on the left side — Durant maneuver 
[18]. Another course of action may involve administration 
of inotropic positive agents, and even cardiocentesis. The 
size of the complication may be changed with the use of the 
hyperbaric chamber, as this will reduce the volume of gas; 
even postponed hyperbaric therapy gives a good effect [28].
Prevention is the key issue as far as HM-related compli-
cations are concerned, which sometimes requires redefini-
tion of the usual approach to hysteroscopy, as was done in 
Norway [28]. The basic task is to train the staff regarding 
the probability of such complications, and to design a local 
procedure plan [18]. Proper monitoring has already been de-
scribed above. The important thing is to consider the choice 
of the correct position - slightly inverted Trendelenburg 
position is the best. The medium delivery systems should 
pump the fluid up to the maximum of 60 mmHg and the 
outflow should be passive. The surgeon should limit the in-
sertion of the hysteroscope to the necessary minimum [28]. 
CONCLUSIONS
HM for the removal of submucous UFs is a safe and ef-
fective treatment in patients with normal size of the uterus 
and with no more than a few UFs. The procedure should be 
preceded by careful preparation, especially adequate diag-
nosis with the best methods available. 3D ultrasound is both, 
inexpensive and effective, but the test must be performed 
by a well-trained sonographer. In such scans, FMM can be 
properly checked e.g. using the tomography like sequence. 
The second important point is the adequate qualification 
for the procedure and the choice of the proper method. In 
case of HM, where there is a high risk for complications, the 
procedure should be performed by expert staff. At present, 
no technique has proven to be superior over others, but the 
method should reduce the potential risk in very difficult cases, 
e.g. cold loop or direct laparoscopic supervision. Staff should 
also be trained in laparoscopic skills in case of complications 
which could be treated with the use of this method. It should 
also be considered whether the patient will benefit from 
laparoscopic myomectomy. It is important to have proper 
operational protocol which will ensure minimum risk of OHIA 
or VAE. Severe media-related complications occur more fre-
quently with hypotonic solutions and in women with associ-
ated illnesses, which is why caution is advised. 
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